TY - JOUR
T1 - New approaches in brain tumor therapy using gene transfer and antisense oligonucleotides
AU - Yung, W. K.A.
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 1994
Y1 - 1994
N2 - Despite advances in neurosurgery, radiation, and chemotherapy, the prognosis of patients with malignant brain tumors remains grim. New approaches, particularly molecular strategies, have become the clinician's and scientist's hope for the future in brain tumor therapy. Several molecular approaches have been shown to have in vitro and in vivo activities. These approaches include the use of retroviral vectors, herpes simplex viruses, antisense vectors, and antisense oligonucleotides. Preclinical studies of the retroviral vector have already been extended to clinical trials, clearly demonstrating the clinical potential of these molecular therapies.
AB - Despite advances in neurosurgery, radiation, and chemotherapy, the prognosis of patients with malignant brain tumors remains grim. New approaches, particularly molecular strategies, have become the clinician's and scientist's hope for the future in brain tumor therapy. Several molecular approaches have been shown to have in vitro and in vivo activities. These approaches include the use of retroviral vectors, herpes simplex viruses, antisense vectors, and antisense oligonucleotides. Preclinical studies of the retroviral vector have already been extended to clinical trials, clearly demonstrating the clinical potential of these molecular therapies.
UR - http://www.scopus.com/inward/record.url?scp=0028216810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028216810&partnerID=8YFLogxK
U2 - 10.1097/00001622-199405000-00003
DO - 10.1097/00001622-199405000-00003
M3 - Review article
C2 - 8080851
AN - SCOPUS:0028216810
SN - 1040-8746
VL - 6
SP - 235
EP - 239
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 3
ER -